23 May 2023: Original Paper
Safety and Efficacy of 4 mg·kg Sugammadex for Simultaneous Pancreas-Kidney Transplantation Recipients: A Prospective Randomized Trial
Jiancheng Tang 12ABCDEFG , Rongzhi He 2ABCEF , Lei Zhang 3ABD , Shiyuan Xu 1ABCDEFG*DOI: 10.12659/AOT.940211
Ann Transplant 2023; 28:e940211
Table 1 The patient characteristics and details of surgery between the 2 groups.
| Group S | Group N | P* value | |
|---|---|---|---|
| Gender (M: F) | 13/11 | 12/12 | |
| Age(yr) | 42±3 | 46±5 | |
| Weight(kg) | 68.3±3.6 | 67.6±2.9 | |
| ASA II/III | 10/10 | 9/11 | |
| BMI, kg/m | 27.3±1.5 | 28.0±1.7 | |
| Education years(12 yr) | 0/15/5 | 1/16/3 | |
| Duration of the operation, min | 488±42 | 491±49 | |
| Duration of the anesthesiology, min | 612±22 | 624±30 | |
| Haemodialysis before operation, h | 33.3±2.5 | 34.3±3.0 | |
| Cumulative rocuronium dose, mg/kg | 5.98 (4.57–7.13) | 6.05 (4.61–7.21) | |
| Spontaneous RR, breaths/min | 15±2 | 14±3 | |
| Spontaneous TV, ml/kg | 7.8±0.5 | 7.6±0.2 | |
| ETAG (MAC) | 0.82±0.22 | 0.81±0.25 | |
| Recovery of TOFr to 0.9, min | 4.4 (3.5–5.9) | 49.5 (32.5–61.8) | |
| Duration of PACU stay | 38±12 | 65±21 | |
| Requirement for admission to ICU | 0 | 2 (8.4%) | |
| Reintubation | 0 | 0 | |
| Returns to the OR | 0 | 0 | |
| Supplemental oxygen requirements | 0 | 4 (16.8%) | |
| Pulmonary atelectasis | 0 (0) | 2 (8.4%) | |
| Pneumonia | 1 (4.2%) | 3 (12.5%) | |
| Hyoxemia | 1 (4.2%) | 4 (16.7%) | |
| Volume of urine(ml·kg·h) | ≥1 | ≥1 | |
| Renal graft failure | 0 | 0 | |
| Pancreas graft failure | 0 | 0 | |
| Graft survival rate | 100% | 100% | |
| Data are presented as number (%) or mean±SD (standard deviation, SD), P value * Chi-square test (2×n) and independent sample t test. | |||